442 Entecavir 10 mg is consistently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine-refractory patients
| Autor: | Schiff, E.R., Chang, T.T., Gish, R.G., Hadziyannis, S., Cianciara, J., Rizzetto, M., Pastore, G., Cross, A., Hindes, R. |
|---|---|
| Zdroj: | In Journal of Hepatology 2004 40 Supplement 1:131-131 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect